Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Barclays Downgrades Lilium to Underweight, Lowers Price Target to $1

Barclays Downgrades Lilium to Underweight, Lowers Price Target to $1

Barclays analyst David Zazula downgrades Lilium (NASDAQ:LILM) from Equal-Weight to Underweight and lowers the price target from $2 to $1.

byBenzinga Newsdesk

December 7, 2022

1 minute read

Barclays analyst David Zazula downgrades Lilium (NASDAQ:LILM) from Equal-Weight to Underweight and lowers the price target from $2 to $1.

Analyst Ratings

5 Analysts Have This to Say About Vail Resorts

By Benzinga Insights

September 29, 10:00 AM

Over the past 3 months, 5 analysts have published their opinion on Vail Resorts (NYSE:MTN) stock. These analysts…

MTN

Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $21

By Benzinga Newsdesk

August 23, 9:25 AM

Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price target from $37 to $21.

STRO

Price Over Earnings Overview: JPMorgan Chase

By Benzinga Insights

September 1, 3:15 PM

In the current market session, JPMorgan Chase Inc. (NYSE:JPM) share price is at $147.02, after a 0.47% spike.…

JPM

Axcelis Technologies Q3 EPS $1.21 Beats $1.13 Estimate, Sales $229.18M Beat $224.38M Estimate

By Michael Horton

November 2, 5:17 PM

Axcelis Technologies (NASDAQ:ACLS) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.13 by 7.08 percent. This is a 49.38 percent increase over earnings of $0.81 per share from

ACLS

Barclays Downgrades Lilium to Underweight, Lowers Price Target to $1

Related Posts

5 Analysts Have This to Say About Vail Resorts

Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $21

Price Over Earnings Overview: JPMorgan Chase

Axcelis Technologies Q3 EPS $1.21 Beats $1.13 Estimate, Sales $229.18M Beat $224.38M Estimate